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IN T R O D U C T IO N
A  relationship between the endocrine system 
and breast cancer was first demonstrated by 
Beatson in 1896, when he obtained some bene- 
fit from  oophorectom y in two patients with 
advanced disease. U ntil that time the treat- 
m ent of breast cancer was lim ited to removal 
of the mamma and excision of superficial 
metastatic or recurrent nodules. T h e practice 
of castrating cows to maintain lactation after 
calving suggested to Beatson that the ovaries 
must be concerned in some way with the regul- 
ation of the physiological processes of the 
breast.
Reporting his findings to the M edico- 
Chirurgical Society of Edinburgh, Beatson 
summed u p :
“ T h e  conclusion I draw from two cases I 
have brought under notice is this —  that 
we must look in the fem ale to the ovaries as 
th e seat of the exciting cause of carcinoma, 
certainly of the mamma . . . . ”
H e further emphasised :
1. “ T h at there seems to be evidence of the 
ovaries and testicles having control in 
the human body over local proliferation 
of epithelium ” .
2. “ T h at the removal of the tubes and 
ovaries has effect on the local prolifer­
ation of epithelium which occurs in 
carcinoma of the mamma . . . . ”
3. “ T h at the effect is best seen in cases of 
carcinoma in young people, a class of 
case where local removal of the disease is 
often unsatisfactory.”
W ith in  the next decade, Boyd (1900) and 
L ett (1905) confirmed Beatson’s observations 
and showed that about one-third of patients 
responded favourably to oophorectomy. It is 
interesting that no im provem ent in this figure 
has taken place since then, for the Jo in t C o m ­
mittee of the Am erican M edical Association on 
Ablative Procedures in Breast Cancer reported 
that objective tumour regression occurred in 
29%  of women castrated before or during the 
menopause (Taylor, 1962).
In the seventy years since Beatson’s pioneer 
effort the concept of hormone-dependence has 
becom e an accepted biological characteristic of 
certain tumours, particularly of the breast and 
prostate. It had its origin in the classical 
observations of Huggins and his colleagues who 
demonstrated that in dogs not only are the 
physiological processes of the prostate under 
endocrine control but that tumours of the 
glands regress after castration or in response to 
the administration of oestrogens (Huggins and 
Clark, 1940). It was subsequently shown that 
cancer of the human prostate could be influ­
enced in a similar way.
T h e  developm ent of our understanding, 
albeit imperfect, of the relationship between 
endocrine status and breast cancer is the result
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of a fruitful alliance of clinical practice, bio­
chemical investigation and animal experiment. 
Som e of the most significant contributions in 
these fields are discussed below.
EXPERIMENTAL TUMOURS IN ANIMALS
A great deal of research has been carried out 
on experimental tumours, particularly in the 
United States and a voluminous literature has 
accumulated. Three main lines of investigation 
have been followed.
1. Induction of tumours by hormones
O nly three years after Doisy had isolated the 
first crystalline oestrogen, Lacassagne (1932) 
induced mammary cancer in male m ice by 
repeated injections of the hormone. M any 
workers since have confirmed that oestrogens 
may promote tumour growth in several species 
(Noble, 1957).
T h e  breast is not the only organ to be 
affected. Oestrogen administration has yielded 
lym phoid tumours in mice, chromophobe 
tumours of the anterior pituitary fibromyomata 
of the uterus in guinea pigs, malignant tumours 
of the cervix uteri, malignant renal tumours in 
male golden hamsters and interstitial cell 
tumours of testes in mice.
Although oestrogens are the most potent, 
other hormones have been found also to induce 
tumours. M oon and his colleagues (1950), for 
example, described lymphosarcomata, adrenal 
cortical and ovarian tumours in rats receiving 
injections of pituitary growth hormone.
These examples demonstrate the carcino­
genic effects of the administration of exogenous 
hormones. T h e  secretion of edogenous horm­
ones may be altered by suitable manipulation 
of the endocrine system. Elegant experiments 
which demonstrate the interdependence of 
endocrine organs, and the oncogenic potential 
of interference with the feed-back mechanisms 
were reported by Biskind and Biskind (1944). 
T h ey excised both ovaries from rats and trans­
planted one of them into the spleen. Ovarian 
oestrogen was thus liberated directly into the 
portal circulation and inactivated by the liver. 
They concluded that the resultant excessive 
production of anterior pituitary gonadotro­
phins was responsible for the granulosa-cell 
tumours and luteomata in the transplanted 
ovary.
2. The effects of hormones on spontaneous mammary
tumours
Spontaneous fibroadenomata occur in about 
fifty per cent of elderly female rats of the
Sprague-Dawley strain. These tumours arc 
readily transplanted into young rats and their 
experimental value depends upon their respon- 
siveness to alterations in the anim al’s endocrine 
environm ent.
A  biphasic effect on the growth of the 
tumour has been observed during the adm inis­
tration of oestrogen both in intact (M illar and 
N oble, 1954) and ovariectomised rats (Huggins, 
e t a l., 1956). Small doses of oestrogen promote, 
and large doses inhibit, the growth of the 
tumours. T h e  effects of androgenic steroids 
have also been intensively investigated by 
Huggins and M ainzer (1957) and in general, 
they arc inhibitory.
3. Endocrine factors influencing hydrocarbon-induced 
mammary cancers
T h e two most useful m am m ary carcinogens 
are 3-M ethyleholanthrene and 9, 10-Dim ethyl- 
1 , 2-Benzanthracene (D M B A ). T h e  tumours 
appear within a few weeks in response to a 
single  intragastric instillation or intravenous 
injection (Huggins, Briziarelli and Sutton, 
1959). T h ey are adenocarcinomas histologically 
similar to human tumours. T h ey are also 
hormone-dependent, and regression or dis- 
appearance of the tumours occurs after oophor- 
ectomy, after hypophysectomy and in response 
to the exhibition of exogenous steroids.
On the basis of their growth characteristics 
the tumours can be classified into three bio­
logical types. Som e grow to a certain size, then 
regress spontaneously; some remain static after 
an initial period of growth: and others continue 
to enlarge throughout their life-history (Young, 
ct a l, 1963).
M any of these features are characteristic of the 
human disease, and the hydrocarbon-induced 
mammary tumour is, therefore, a unique experi­
mental model for intensive investigation of the 
endocrine factors concerned in the induction 
and m aintenance of breast cancer.
C L IN IC A L  O B S E R V A T IO N S
In clinical practice, alteration of the endo- 
crine state of patients has been achieved either 
by the administration of steroid hormones or 
by ablation of endocrine organs. Such measures 
have generally been lim ited to the treatment of 
advanced m alignant disease.
Endocrine Ablative Procedures 
1. Oophorectomy
Since B eatson’s original observations there 
have been many confirmatory reports of the 
value in certain cases of removal of the ovaries.
Elimination of ovarian function has also been 
achieved by radiotherapy, and Douglas (1952) 
reported a favourable response in 20 per cent 
of patients with advanced disease. A  major 
debate has now centred on the timing of 
castration, which may be done either as a pro- 
phylactic measure at an early stage in the disease 
or deferred until metastases have appeared. 
From an extensive review of the relevant liter- 
ature Lewison (1962) concluded that thera- 
peutic oophorectomy is an effective palliative 
procedure in about 25 per cent of patients and 
that there is a well defined trend towards 
prolonged life expectancy and improved survival 
rate from prophylactic castration whether 
achieved by surgery or by irradiation.
Oophorectomy is occasionally necessary in 
young women for the treatment of gynaeco- 
logical disorders. Careful follow-up studies 
(Lilienfield, 1956; Hirayama and Wynder, 1962) 
indicate that in these women there is a reduced 
incidence of breast cancer in later years, parti- 
cularly if the operation was done before the 
age of 37 years. Bilateral oophorectomy offers 
the greater protection, but even women who 
have had one ovary excised are significantly less 
prone to the subsequent development of cancer. 
These reports suggest that the ovary and its 
secretions are important in the induction as 
well as the maintenance of human breast 
cancer.
2. Adrenalectomy
Removal of the adrenal glands is designed to 
remove the main source of extra-ovarian sex 
hormones. It is usually combined with oophor­
ectomy even in post-menopausal women in 
whom secretion of ovarian hormones continues 
although the uterus atrophies.
In 1945 Huggins and Scott obtained tumour 
remission following bilateral adrenalectomy in 
a man with advanced prostatic cancer. Survival 
lasted only four months in spite of the admini­
stration of deoxycorticosterone and a high salt 
intake. By 1952 cortisone was readily available 
and Huggins and Bergenstal successfully oper- 
ated on seven patients with breast cancer of 
whom three, including one man, responded 
favourably. Since this time, many reports have 
indicated a variable degree of success, but 
remission occurs in about one-third of patients 
who are submitted to adrenalectomy and 
oophorectomy.
3. Hypophysectomy
This operation was introduced by Luft and 
Olivecrona in 1953. They reported (1958) a 
total remission rate of 44 per cent —  regression 
of tumour in 29 per cent, and arrest of disease 
in 15  per cent of patients. A  comprehensive 
survey of the value of adrenalectomy and hypo- 
physectomy has been conducted by the Joint 
Committee of the American Medical Assoc­
iation (1961). The results from twelve 
American Clinics (representing a total of 673 
patients) demonstrate no difference between 




The isolation of a crystalline oestrogenic 
hormone by Doisy in 1929 heralded an explosive 
development of steroid biochemistry, leading 
eventually to the elaboration of synthetic 
oestrogens. The value of these compounds in 
the treatment of advanced malignant disease 
was demonstrated by Haddow, W atkinson and 
Paterson (1944). Perhaps the most significant 
feature of these studies for the clinician is that 
for the first time, they enabled him to write a 
prescription for the treatment of cancer. This 
marks the origin of chemotherapy in malignant 
disease.
Oestrogen therapy is of greatest value in post­
menopausal women in whom tumour regression 
occurs in about 35 per cent with a mean survival 
time of 27 months compared with 10  months 
in non-responsive patients (Council on Drugs 
of the American Medical Association, 1960).
2. Androgens
Loesser first demonstrated in 1939 that be­
tween 20 per cent and 25 per cent of patients 
respond to androgen administration, irrespective 
of menopausal state. Survival times recorded 
by the Council on Drugs (i960) were 19 
months and less than 10 months in responsive 
and non-responsive patients respectively. 
Hirsutism, acne, deepening of the voice and 
increase in libido are displeasing side-effects 
which have dissuaded many clinicians, and 
patients from continuing treatment. Numerous 
steroid derivatives have been investigated by 
the Co-operative Breast Cancer Group (1964) 
in an attempt to find compounds which are 
non-virilising and yet retain their therapeutic 
effectiveness. Although some success has been 
achieved it is doubtful whether these com- 




High doses of corticosteroids are beneficial in 
castrated patients and are believed to act by 
inhibition of the adrenal cortex and consequent 
reduced production of oestrogen. Prednisolone, 
a synthetic corticosteroid, is more effective than 
cortisone and causes less water retention.
Progesterone appears to have little effect but 
a synthetic progestational compound, 9 α- 
bromo-1 1-ketoprogesterone, studied by Golden- 
berg and Hayes (1959) produced a 20 per cent 
remission. Combinations of oestrogen and 
progesterone may be more effective. Stimul­
ated by the observation that hydrocarbon- 
induced experimental tumours responded to 
administration of high doses of oestradiol and 
progesterone, Landau and his colleagues (1962) 
tried the combination in 15  patients, of whom 
9 responded though only for a short time. 
Recently, Stoll (1967) has reported a 20 per 
cent response in patients receiving the oral 
contraceptive, Lyndiol, in which an oestrogen 
and progestin are combined.
Effectiveness of Treatment
It is evident from this brief outline that 
about one-third of patients respond to the 
administration of hormones or to endocrine 
ablative procedures. Adverse reactions to treat­
ment do occur, however. W ilson, Jessiman and 
Moore (1958) have noted exacerbation of 
metastatic disease following oophorectomy and 
adrenalectomy, and Cade (19 58) has reported 
similar effects from the administration of 
androgens and oestrogens. The results in 
human patients prompt comparison with the 
biphasie effects of oestrogens and androgens 
observed in experimental tumours, and em­
phasise our present ignorance of the funda­
mental relationships between hormones and 
growth.
Much has been written and many opinions 
have been expressed on the value of certain 
clinical criteria for the selection of patients 
with metastatic disease for major endocrine 
surgery. In his comprehensive review of this 
subject Fairgrieve (1966) concludes that two 
categories of patient are most likely to benefit; 
those with a long “ free-interval” , that is, in 
whom more than a year has elapsed between 
primary treatment and first recurrence, and 
those with skeletal or skin metastases. He 
emphasises the importance of assessing the 
extent and type of metastases. Slowly growing 
cutaneous or lymph node recurrences are per- 
haps best treated" by local surgery or radio- 
therapy. Major surgery is inappropriate in pre- 
terminal states when life expectancy is limited.
Between these two extremes are patients with 
metastatic disease which is progressive and/or 
symptomatic for whom endocrine ablative 
procedures should be reserved.
The main problem which besets the clinician 
is his inability to forecast for the individual 
patient whether or not a favourable reponse 
will be obtained. It is towards this end that 
the greatest efforts have been made in the last 
decade.
BIOCHEM ICAL INVESTIGATIONS
One of the most rewarding features of 
medical practice in recent years has been an 
awareness of the need for collaborative efforts 
by members of different disciplines, especially 
in assessing complex biological problems. Not 
least successful among the alliances so estab­
lished has been the team comprising endocrino­
logist, biochemist, surgeon and radiotherapist. 
Much pioneer work along these lines has been 
actively pursued in Edinburgh.
The principal approach of the steroid bio­
chemist has been the determination of steriod 
metabolites in urine and their relationship to 
clinical observations.
Urinary Oestrogens
Animal experiment and clinical observation 
indicated that oestrogen played a major role 
in the induction and maintenance of breast 
cancer. The elaboration of reliable methods for 
the analysis of urinary oestrogens (Brown, 1955 
and Bauld, 1956) provided the means for 
intensive collaborative activity in Edinburgh. 
Strong and his colleagues (1956) found no 
correlation between pre-treatment oestrogen 
levels and subsequent response to the adminis­
tration of stilboestrol or endocrine ablative 
operations. Subsequent reports from other 
centres have confirmed these observations.
Attempts to correlate the clinical result with 
changes in urinary oestrogen levels occurring 
after ablative procedures similarly have been 
disappointing. Some patients improve in spite 
of continuing high levels of urinary oestrogen 
and others deteriorate when oestrogen excretion 
has fallen to negligible amounts (Brown, et al., 
1959)-
Several studies have indicated, however, that 
post-menopausal women with breast cancer 
differ from the normal population by an in­
creased excretion of oestrogen. The physio­
logical significance of this finding remains 
obscure, and more detailed study is required 
to establish its possible relationship to the 
development of breast cancer.
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Overall, the efforts to relate oestrogen excre­
tion to the course and prognosis of human 
breast cancer have been inconclusive.
U rinary  A ndrogens and  C orticosteroids
' T h e  estimation of urinary androgen and 
corticosteroid metabolites has proved the most 
hopeful approach so far. A  major contribution 
in this field has resulted from the collaborative 
studies in London by G u y ’s Hospital and the 
Imperial Cancer Research Fund. W orkers 
there have investigated patients with advanced 
disease, patients with early breast cancer and 
normal women.
1. Advanced breast cancer
Urine was collected before operation from 
patients treated by adrenalectomy or hypophy- 
sectomy and estimations were made of gonado­
trophins, androgen, oestrogen, corticosteriods 
and progesterone metabolites. B y retrospective 
analysis of the data it was found that patients 
who responded satisfactorily to the operation 
were characterised by a relatively low excretion 
of corticosteroids and relatively high levels of 
urinary androgens. A  reasonable distinction 
between the responsive and unresponsive 
clinical groups was obtained by expressing 17- 
hydroxy corticosteroids (17-O H CS) and 11- 
deoxy-17-oxosteroids as a simple ratio.
A  more sophisticated statistical approach 
led to the formulation of a discriminant func­
tion which takes the form
80-80 [17-O H C S (mgm/24 hrs.)] + 
aetiocholanolone* (μ gs/24 hrs.)
T h e design of the formula is such that a 
negative or positive number is obtained depend­
ing on the relative values of the steroids. By 
this means a clearer distinction between the 
clinical groups was obtained. A  significant 
majority of patients with a “ positive discrimin­
ant”  responded to adrenalectomy or hypo- 
physectomy whereas the results of treatment in 
the “ negative discriminant” category were 
generally poor (Bulbrook, et al., 1962).
W hen  the discriminant function is con­
sidered in association with clinical observations 
a group of poor-risk patients with advanced 
disease is revealed. Remission is obtained in 
only 2 per cent of “ discriminant-negative” 
patients in whom the primary tumour was 
noted within six years after the menopause 
and in whom recurrence had appeared within 
two years of primary treatment.
2. Early b reast cancer
There are indications that the relationships 
originally demonstrated in advanced breast
*A etiocholanolone is one of the urinary androgen 
excretion products.
cancer also obtain at an early stage of the 
disease. A  negative discriminant function is a 
rare finding in normal women under the age of 
60 years but has been observed in about 50 per 
cent of patients with early breast cancer. In 
these patients the incidence of recurrence is 
four times higher and the death rate is eight 
times greater than those with a positive dis­
criminant (Bulbrook, et al., 1964).
3. Prospective studies on norm al w om en
T h e preceding observations suggest that in 
some women with breast cancer there is an 
abnormality in the secretion of androgens and 
corticosteriods. Prognosis is poor in these 
patients, perhaps because the tumour has be­
com e hormone-independent. T o  determine 
whether the abnormality precedes the develop­
ment of disease or results from the presence of 
the tumour a prospective survey was set up in 
Guernsey in 1961.
Alm ost 5,000 healthy female volunteers from 
this relatively closed population have provided 
one com plete collection of urine. T o  date, 
breast cancer has developed in nineteen of the 
women. Analysis of the results suggests that 
the excretion of androgen and corticosteroid 
metabolites was abnormal in a significant pro­
portion of the patients prior to the develop­
m ent of the disease (Bulbrook and Hayward, 
1967).
CONCLUSION
T h e management of breast cancer presents 
a formidable challenge to the clinician. Inten­
sive research on the relationship of the 
endocrine system to the induction and main­
tenance of mammary tumours has provided 
some insight into the nature of the disease. 
Some tumours appear to regress after alteration 
of the hormonal environment in which they 
have developed, others do not. It is not yet 
possible to determine the biological nature of a 
particular tumour at a sufficiently early stage 
in the disease to orientate the search for 
effective counter-measures. There are indic­
ations however, that poor-risk patients, and 
even healthy women who are “ susceptible”  to 
the disease, m ight be identified by abnormal­
ities of secretion of urinary steroids. It should 
be possible in the future to confirm these 
suggestions and to simplify the measurements 
so that they are more generally available. T here­
after, attempts to produce a more favourable 
endocrine environment might not only be 
possible, but acceptable in a society in which 
hormonal modifications for fertility and birth 
control arc now commonplace.
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A Case for Dissection
In an anonymous monograph in the Library entitled “ An Answer to the Several Attacks which 
have appeared against the University of Edinburgh” the author includes in his refutation of the 
“ calumnies which have been circulated against this University, particularly that lately published in 
the city of Dublin” an interesting little snippet on Edinburgh dissecting habits in the early 19th 
century:
“ Let us figure to ourselves a group of students assembled round a subject. One is cutting out 
an eye, another is making a prize of the heart, which he is proceeding to examine at his leisure, a 
third is grubbing in the entrails, and a fourth practising the insertion of the female catheter; the 
whole party brandishing their scalpels, singing and laughing, as merry as coblers (sic) over their awls. 
Suppose that the lecturer were to come in and to recognise in this one-eyed, mangled, heartless 
creature, the frail remains of the wife of his bosom, the sister, or daughter, whom he had cherished 
with the tenderest affection! How would he be able to bear such a sight? W ould he not start back 
with horror? W ould it not put all his philosophy at once to flight?”
Perhaps they weren't calumnies after all . . .
